450 related articles for article (PubMed ID: 20600025)
1. Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection.
Berg T; Marcellin P; Zoulim F; Moller B; Trinh H; Chan S; Suarez E; Lavocat F; Snow-Lampart A; Frederick D; Sorbel J; Borroto-Esoda K; Oldach D; Rousseau F
Gastroenterology; 2010 Oct; 139(4):1207-17. PubMed ID: 20600025
[TBL] [Abstract][Full Text] [Related]
2. Similar evolution of hepatitis B virus quasispecies in patients with incomplete adefovir response receiving tenofovir/emtricitabine combination or tenofovir monotherapy.
Lavocat F; Dény P; Pichoud C; Al Hawajri N; Kitrinos K; Borroto-Esoda K; Zoulim F
J Hepatol; 2013 Oct; 59(4):684-95. PubMed ID: 23742912
[TBL] [Abstract][Full Text] [Related]
3. Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B.
Fung S; Kwan P; Fabri M; Horban A; Pelemis M; Hann HW; Gurel S; Caruntu FA; Flaherty JF; Massetto B; Dinh P; Corsa A; Subramanian GM; McHutchison JG; Husa P; Gane E
Gastroenterology; 2014 Apr; 146(4):980-8. PubMed ID: 24368224
[TBL] [Abstract][Full Text] [Related]
4. Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B.
Patterson SJ; George J; Strasser SI; Lee AU; Sievert W; Nicoll AJ; Desmond PV; Roberts SK; Locarnini S; Bowden S; Angus PW
Gut; 2011 Feb; 60(2):247-54. PubMed ID: 21036792
[TBL] [Abstract][Full Text] [Related]
5. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
Marcellin P; Heathcote EJ; Buti M; Gane E; de Man RA; Krastev Z; Germanidis G; Lee SS; Flisiak R; Kaita K; Manns M; Kotzev I; Tchernev K; Buggisch P; Weilert F; Kurdas OO; Shiffman ML; Trinh H; Washington MK; Sorbel J; Anderson J; Snow-Lampart A; Mondou E; Quinn J; Rousseau F
N Engl J Med; 2008 Dec; 359(23):2442-55. PubMed ID: 19052126
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis B virus wild-type and rtN236T populations show similar early HBV DNA decline in adefovir refractory patients on a tenofovir-based regimen.
Svarovskaia ES; Curtis M; Zhu Y; Borroto-Esoda K; Miller MD; Berg T; Lavocat F; Zoulim F; Kitrinos KM
J Viral Hepat; 2013 Feb; 20(2):131-40. PubMed ID: 23301548
[TBL] [Abstract][Full Text] [Related]
7. Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study.
Pellicelli AM; Barbaro G; Francavilla R; Romano M; Barbarini G; Mazzoni E; Mecenate F; Paffetti A; Barlattani A; Struglia C; Villani R; Nauri L; Nosotti L; Armignacco O; Ferri F; Camporiondo MP; Soccorsi F;
Clin Ther; 2008 Feb; 30(2):317-23. PubMed ID: 18343270
[TBL] [Abstract][Full Text] [Related]
8. Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations.
Tan J; Degertekin B; Wong SN; Husain M; Oberhelman K; Lok AS
J Hepatol; 2008 Mar; 48(3):391-8. PubMed ID: 18199519
[TBL] [Abstract][Full Text] [Related]
9. No resistance to tenofovir disoproxil fumarate through 96 weeks of treatment in patients with lamivudine-resistant chronic hepatitis B.
Corsa AC; Liu Y; Flaherty JF; Mitchell B; Fung SK; Gane E; Miller MD; Kitrinos KM
Clin Gastroenterol Hepatol; 2014 Dec; 12(12):2106-12.e1. PubMed ID: 24929235
[TBL] [Abstract][Full Text] [Related]
10. No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus.
Snow-Lampart A; Chappell B; Curtis M; Zhu Y; Myrick F; Schawalder J; Kitrinos K; Svarovskaia ES; Miller MD; Sorbel J; Heathcote J; Marcellin P; Borroto-Esoda K
Hepatology; 2011 Mar; 53(3):763-73. PubMed ID: 21374657
[TBL] [Abstract][Full Text] [Related]
11. 96 weeks combination of adefovir dipivoxil plus emtricitabine vs. adefovir dipivoxil monotherapy in the treatment of chronic hepatitis B.
Hui CK; Zhang HY; Bowden S; Locarnini S; Luk JM; Leung KW; Yueng YH; Wong A; Rousseau F; Yuen KY; Naoumov NN; Lau GK
J Hepatol; 2008 May; 48(5):714-20. PubMed ID: 18207280
[TBL] [Abstract][Full Text] [Related]
12. Tenofovir disoproxil fumarate is superior to lamivudine plus adefovir in lamivudine-resistant chronic hepatitis B patients.
Yang DH; Xie YJ; Zhao NF; Pan HY; Li MW; Huang HJ
World J Gastroenterol; 2015 Mar; 21(9):2746-53. PubMed ID: 25759545
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of HBV DNA decay kinetics in patients containing both rtM204V/I mutant and wild-type HBV subpopulations during tenofovir DF (TDF) monotherapy or combination therapy with emtricitabine (FTC)/TDF.
Liu Y; Fung S; Gane EJ; Dinh P; Flaherty JF; Svarovskaia ES; Miller MD; Kitrinos KM
J Med Virol; 2014 Sep; 86(9):1473-81. PubMed ID: 24861361
[TBL] [Abstract][Full Text] [Related]
14. Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA.
Chan HL; Chan CK; Hui AJ; Chan S; Poordad F; Chang TT; Mathurin P; Flaherty JF; Lin L; Corsa A; Gaggar A; Subramanian GM; McHutchison JG; Lau G; Lee S; Gane EJ
Gastroenterology; 2014 May; 146(5):1240-8. PubMed ID: 24462735
[TBL] [Abstract][Full Text] [Related]
15. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B.
Heathcote EJ; Marcellin P; Buti M; Gane E; De Man RA; Krastev Z; Germanidis G; Lee SS; Flisiak R; Kaita K; Manns M; Kotzev I; Tchernev K; Buggisch P; Weilert F; Kurdas OO; Shiffman ML; Trinh H; Gurel S; Snow-Lampart A; Borroto-Esoda K; Mondou E; Anderson J; Sorbel J; Rousseau F
Gastroenterology; 2011 Jan; 140(1):132-43. PubMed ID: 20955704
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone.
Shim JH; Suh DJ; Kim KM; Lim YS; Lee HC; Chung YH; Lee YS
Hepatology; 2009 Oct; 50(4):1064-71. PubMed ID: 19637288
[TBL] [Abstract][Full Text] [Related]
17. Adefovir plus lamivudine are more effective than adefovir alone in lamivudine-resistant HBeAg- chronic hepatitis B patients: a 4-year study.
Vassiliadis TG; Giouleme O; Koumerkeridis G; Koumaras H; Tziomalos K; Patsiaoura K; Grammatikos N; Mpoumponaris A; Gkisakis D; Theodoropoulos K; Panderi A; Katsinelos P; Eugenidis N
J Gastroenterol Hepatol; 2010 Jan; 25(1):54-60. PubMed ID: 19780875
[TBL] [Abstract][Full Text] [Related]
18. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease.
Liaw YF; Sheen IS; Lee CM; Akarca US; Papatheodoridis GV; Suet-Hing Wong F; Chang TT; Horban A; Wang C; Kwan P; Buti M; Prieto M; Berg T; Kitrinos K; Peschell K; Mondou E; Frederick D; Rousseau F; Schiff ER
Hepatology; 2011 Jan; 53(1):62-72. PubMed ID: 21254162
[TBL] [Abstract][Full Text] [Related]
19. Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy.
Kim HJ; Park JH; Park DI; Cho YK; Sohn CI; Jeon WK; Kim BI
J Gastroenterol Hepatol; 2010 Aug; 25(8):1374-80. PubMed ID: 20659226
[TBL] [Abstract][Full Text] [Related]
20. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy.
van Bömmel F; Zöllner B; Sarrazin C; Spengler U; Hüppe D; Möller B; Feucht HH; Wiedenmann B; Berg T
Hepatology; 2006 Aug; 44(2):318-25. PubMed ID: 16871563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
